98 related articles for article (PubMed ID: 8056703)
1. In-vitro slime production by Staphylococcus epidermidis in presence of subinhibitory concentrations of ciprofloxacin, ofloxacin and sparfloxacin.
Pérez-Giraldo C; Rodríguez-Benito A; Morán FJ; Hurtado C; Blanco MT; Gómez-García AC
J Antimicrob Chemother; 1994 Apr; 33(4):845-8. PubMed ID: 8056703
[No Abstract] [Full Text] [Related]
2. Antistaphylococcal activities of sparfloxacin (CI-978; AT-4140), ofloxacin, and ciprofloxacin.
Chaudhry AZ; Knapp CC; Sierra-Madero J; Washington JA
Antimicrob Agents Chemother; 1990 Sep; 34(9):1843-5. PubMed ID: 2285304
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of sparfloxacin and three other fluoroquinolones against methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis.
Smith KR; Cobbs CG
Eur J Clin Microbiol Infect Dis; 1992 Jan; 11(1):55-8. PubMed ID: 1314175
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
Malmborg AS; Ahlén S
Chemotherapy; 1993; 39(1):32-5. PubMed ID: 8383030
[TBL] [Abstract][Full Text] [Related]
5. In vitro activities of five quinolones against Chlamydia pneumoniae.
Hammerschlag MR; Hyman CL; Roblin PM
Antimicrob Agents Chemother; 1992 Mar; 36(3):682-3. PubMed ID: 1320366
[TBL] [Abstract][Full Text] [Related]
6. Interaction between biofilms formed by Staphylococcus epidermidis and quinolones.
Yassien M; Khardori N
Diagn Microbiol Infect Dis; 2001 Jul; 40(3):79-89. PubMed ID: 11502373
[TBL] [Abstract][Full Text] [Related]
7. In-vitro and in-vivo antibacterial activity of CFC-222, a new fluoroquinolone.
Kim JH; Choi KH; Kim JW; Lee JH; Choi EC; Kim BK
J Antimicrob Chemother; 1998 Feb; 41(2):223-9. PubMed ID: 9533464
[TBL] [Abstract][Full Text] [Related]
8. In-vitro activity of three fluoroquinolones, cefotaxime and clindamycin against staphylococci.
Schumacher-Perdreau F; Peters G
Zentralbl Bakteriol; 1995 Oct; 282(4):389-93. PubMed ID: 9810661
[TBL] [Abstract][Full Text] [Related]
9. Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria.
Goldstein EJ; Citron DM
Antimicrob Agents Chemother; 1992 May; 36(5):1158-62. PubMed ID: 1324640
[TBL] [Abstract][Full Text] [Related]
10. Antistaphylococcal and antistreptococcal killing kinetics of ciprofloxacin, ofloxacin, sparfloxacin, and trovafloxacin.
Prenna M; Montanari MP; Mingoia M; Biavasco F; Ripa S; Varaldo PE
Eur J Clin Microbiol Infect Dis; 1998 Nov; 17(11):816-9. PubMed ID: 9923533
[No Abstract] [Full Text] [Related]
11. Cross-resistance analysis for clinafloxacin compared with ciprofloxacin, fleroxacin, ofloxacin, and sparfloxacin using a predictor panel of ciprofloxacin-resistant bacteria.
Cormican MG; Jones RN
J Antimicrob Chemother; 1995 Aug; 36(2):431-4. PubMed ID: 8522474
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin.
Rastogi N; Goh KS
Antimicrob Agents Chemother; 1991 Sep; 35(9):1933-6. PubMed ID: 1952872
[TBL] [Abstract][Full Text] [Related]
13. Phagocytosis and killing of slime-producing Staphylococcus epidermidis bypolymorphonuclear leukocytes. Effects of sparfloxacin.
Morán FJ; García C; Pérez-Giraldo C; Hurtado C; Blanco MT; Gómez-García AC
Rev Esp Quimioter; 1998 Mar; 11(1):52-7. PubMed ID: 9795290
[TBL] [Abstract][Full Text] [Related]
14. Anti-staphylococcal activity of temafloxacin, ciprofloxacin, ofloxacin and enoxacin.
Barry AL; Fuchs PC
J Antimicrob Chemother; 1991 Nov; 28(5):695-9. PubMed ID: 1663929
[TBL] [Abstract][Full Text] [Related]
15. Activity of sparfloxacin on Staphylococcus epidermidis attached to plastic catheters.
Pascual A; García I; Ramirez de Arellano E; Perea EJ
J Antimicrob Chemother; 1995 Aug; 36(2):425-30. PubMed ID: 8522473
[TBL] [Abstract][Full Text] [Related]
16. Antistaphylococcal activity of the fluoroquinolones CI-960, PD 131628, sparfloxacin, ofloxacin and ciprofloxacin.
Barry AL; Fuchs PC
Eur J Clin Microbiol Infect Dis; 1991 Mar; 10(3):168-71. PubMed ID: 2060518
[TBL] [Abstract][Full Text] [Related]
17. [In vitro activity of sparfloxacin against methicillin-resistant staphylococci].
Wallrauch C; Voss A; Milatovic D; Braveny I
Arzneimittelforschung; 1995 Jun; 45(6):723-5. PubMed ID: 7646580
[TBL] [Abstract][Full Text] [Related]
18. Spontaneously occurring staphylococcal mutants resistant to clinically achievable concentrations of ciprofloxacin and temafloxacin.
Barry AL; Pfaller MA; Fuchs PC
Eur J Clin Microbiol Infect Dis; 1992 Mar; 11(3):243-6. PubMed ID: 1317799
[TBL] [Abstract][Full Text] [Related]
19. Comparative in vitro activities of new quinolones against coryneform bacteria.
Martínez-Martínez L; Suárez AI; Ortega MC; Perea EJ
Antimicrob Agents Chemother; 1994 Jun; 38(6):1439-41. PubMed ID: 8092851
[TBL] [Abstract][Full Text] [Related]
20. Activity of nadifloxacin against methicillin-resistant Staphylococcus aureus isolated from skin infections: comparative study with seven other fluoroquinolones.
Nishijima S; Nakagawa M; Tsuboi N; Akamatsu H; Horio T; Fujita M; Kawabata S
J Int Med Res; 1996; 24(1):12-6. PubMed ID: 8674789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
